PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT COMPRISING ANTI-IGSF1 ANTIBODY

• Main Authors: LEE, Min-Ki, LEE, Mi-So, BAE, Seung-Geon, SON, Hye-Jin, LEE, Won-Jun
• Format: Patent
• Language: English; French; Korean
• Published: 02.05.2024
• Subjects: CHEMISTRY; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; ORGANIC CHEMISTRY; PEPTIDES; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS

The present invention relates to a pharmaceutical composition for treating colon cancer, biliary tract cancer, or head and neck cancer, comprising an anti-IGSF1 antibody as an active ingredient. When the anti-IGSF1 antibody according to the present invention was treated while co-culturing colon cancer cells, biliary tract cancer cells, or head and neck cancer cells with immune cells, the secretion of Granzyme B, and cytokines IFN-γ and TNF-α was increased. It was confirmed that the growth of colon cancer or biliary tract cancer was inhibited when the antibody was administered to a xenogeneic or allogeneic colon cancer or biliary tract cancer implantation mouse model. Therefore, the anti-IGSF1 antibody of the present invention can be helpful in the treatment of colon cancer, biliary tract cancer, and head and neck cancer. La présente invention concerne une composition pharmaceutique pour le traitement du cancer du côlon, du cancer du tractus biliaire, ou du cancer de la tête et du cou, comprenant un anticorps anti-IGSF1 en tant que principe actif. Lorsque l'anticorps anti-IGSF1 selon la présente invention a été traité tout en co-cultivant des cellules du cancer du côlon, des cellules du cancer du tractus biliaire, ou des cellules du cancer de la tête et du cou avec des cellules immunitaires, la sécrétion de granzyme B, et des cytokines IFN-γ et TNF-α a été augmentée. Il a été confirmé que la croissance du cancer du côlon ou du cancer du tractus biliaire a été inhibée lorsque l'anticorps a été administré à un cancer du côlon xénogénique ou allogénique ou à un modèle de souris d'implantation de cancer du tractus biliaire. Par conséquent, l'anticorps anti-IGSF1 selon la présente invention peut être utile dans le traitement du cancer du côlon, du cancer du tractus biliaire et du cancer de la tête et du cou. 본 발명의 항-IGSF1 항체를 유효성분으로 포함하는 대장암, 담도암 또는 두경부암 치료용 약학 조성물에 관한 것이다. 본 발명에 의한 항-IGSF1 항체를 대장암 세포, 담도암 세포 또는 두경부암 세포와 면역세포를 공동배양 시 처리한 경우, Granzyme B, 및 사이토카인인 IFN-γ 및 TNF-α의 분비가 증가하였다. 상기 항체를 이종 또는 동종의 대장암 또는 담도암 식립 마우스 모델에 투여 시 대장암 또는 담도암의 성장이 억제되는 것을 확인하였다. 따라서, 본 발명의 항-IGSF1 항체는 대장암, 담도암 및 두경부암 치료에 유용하게 사용될 수 있다.